Fig. 3From: Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)Kaplan-Meier curves for overall survival and progression-free survival for SOX+B-mab group (a) and SOX+C-mab group (b) classified by ETS. Solid black line: ETS ≥20, dotted black line: ETS < 20. * indicates < 0.05Back to article page